Setting the benchmark for quality in the research, cultivation and supply of medicinal cannabis
Linneo Health is a global leader in the research, manufacture and supply of medicinal cannabis flowers, extracts and products to pharmaceutical partners developing innovative medicines to patients in need. We are unique, as the world’s only vertically integrated medicinal cannabis supplier, supported by 90 years of unparalleled heritage and experience in the production of strictly regulated pharmaceutical products.
We believe patients around the world deserve to be treated with cannabis medicine of the highest standard. Our unrivalled focus on quality is the cornerstone of our business. Linneo Health is setting the benchmark for quality in the research, cultivation and supply of medicinal cannabis.
We operate one of the most advanced cannabis quality control laboratories in Europe, which we use to analyze our dried flower and cannabis extracts and ensure the highest pharmaceutical grade manufacturing standards of our product are achieved. These include the strictest GACP (Good Agricultural and Collection Practices) cultivation techniques and European GMP (Good Manufacturing Practices) standards.
We go beyond industry best practice at every stage of production, applying the most advanced cultivation techniques and to the highest standard, with precision that can only be achieved from more than 90 years in the manufacture and purification of strictly regulated pharmaceutical products/extracts.
We are continually innovating to deliver the cutting edge in medicinal cannabis for the benefit of people in need. We are committed to the research of effective strains and agricultural techniques for the benefit of patients. We support clinical trials on medical cannabis through our state-of-the-art research facilities. Linneo Health’s research is focused on continual plant improvement. Our team of scientists, agro-chemists and biological engineers are driving innovation in the field using the latest technological advances, including genetic mapping and DNA tracking, to improve plant yield, growth efficiency and quality.
We are not only the trusted partner to address the needs of our customers today, but the partner to trust in developing solutions for the needs of tomorrow, in the rapidly evolving medical cannabis market. We are continually innovating to deliver the cutting edge in medicinal cannabis for the benefit of people in need.
Our European operations center in Southern Spain is optimally positioned to address the needs of its customers through every stage of product development, regulation and handling. Linneo’s expertise provides a clear reference for today’s industry, alongside significant expansion capabilities to support the development of tomorrow’s solutions in a rapidly evolving market.
We are a fully equipped partner to our customers today, allowing them to deliver tailored cannabis medicines to patients around the world. We believe in long term partnerships and can grow and evolve with our customers to address the growing needs of the market.
The commitment, collective effort and high technological component of our R&D activities have allowed us to be awarded with public institutions.
CANNABI+D Project. IDI-20190621
The objective of the project focuses on the development of the production process of cannabis sativa focused on the stages of maturation and drying of the product This project has been co-financed by the European Regional Development Fund (ERDF), within the Pluriregional Operational Program of Spain 2014-2020.
CDTI Contribution: 205,707.16 €.
Linneo Health, S.L., within the framework of the Invest in Spain Programme, has received support from ICEX and co-financing from the European ERDF fund for the implementation of the CANNABI+ project, OBTAINING NEW CANNABIS VARIETIES WITH HIGH CANNABINOID CONTENT. The aim of the project is to obtain varieties of cannabis with a high content of varina cannabinoids and specific terpene profiles from which the active ingredients can be obtained.
Amount of the aid: 200,000 euros.
Call for proposals 2021. File: 2021/26